BLACKSTONE, E. A., & FUHR, J. P. (2012). Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. BioCommunications LLC.
Chicago Style CitationBLACKSTONE, ERWIN A., i JOSEPH P. FUHR. Innovation and Competition: Will Biosimilars Succeed?: The Creation of an FDA Approval Pathway for Biosimilars Is Complex and Fraught With Hazard. Yes, Innovation and Market Competition Are At Stake. But so Are Efficacy and Patient Safety. BioCommunications LLC, 2012.
Cita MLABLACKSTONE, ERWIN A., i JOSEPH P. FUHR. Innovation and Competition: Will Biosimilars Succeed?: The Creation of an FDA Approval Pathway for Biosimilars Is Complex and Fraught With Hazard. Yes, Innovation and Market Competition Are At Stake. But so Are Efficacy and Patient Safety. BioCommunications LLC, 2012.